Q-omics provides the consensus-scored MIR5009 profile across patient tissues and cancer cell-line models. MIR5009 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR5009 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, MIR5009 RNA expression shows 7,877 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, LUSC, and THYM as cancer lineages where MIR5009 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5009 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5009 survival associations across molecular data types. MIR5009 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5009 RNA expression–survival associations across cancer types. High MIR5009 expression shows unfavorable associations in THCA, COAD, LUSC, UCEC, TGCT and THYM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR5009 RNA expression.
This table summarizes MIR5009 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5009. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5009 shows lower tumor expression in LUSC and higher tumor expression in KICH. The LUSC box plot shows higher MIR5009 RNA expression in normal versus tumor tissue (log2 FC = −0.464, t-test p = .017).
This table shows molecular features associated with MIR5009 in patient tissues and cancer cell lines. In patient samples, MIR5009 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
